HOME >> BIOLOGY >> NEWS
Memorial Sloan-Kettering Investigators

hat determines which patients respond to RA and which ones don't have identified a genetic difference between the two groups. APL patients who do well on RA treatment have leukemia that results from the fusion of two genes called PML and RAR-alpha (PML-RAR ), while the leukemia of patients who are resistant to RA is caused by a fusion of the genes PLZF and RAR-alpha (PLZF-RAR ).

To study these minute genetic differences further, Dr. Pandolfi and his colleagues developed two groups of mice: One group harbored the PML-RAR gene fusion, while a second group had the PLZF-RAR gene fusion. Both groups of mice developed APL similar to that seen in humans. In normal cells, certain proteins called transcription factors -- such as RAR -- turn on the expression of other genes with specific functions, such as controlling cell growth and maturation. Using advanced analytical techniques, Dr. Pandolfi's group showed that unlike RAR , proteins produced by the PML-RAR and PLZF-RAR gene fusions turned off, or "repressed," the expression of the cell's genes that normally prompt a cell to mature into a healthy, functioning white blood cell. Because these genes were turned off, the cells didn't mature, and leukemia developed. Moreover, the investigators found that PML-RAR and PLZF-RAR were acting as transcription repressors because of their ability to interact with other proteins. In PML- RAR , these interactions were broken apart by RA, while in PLZF-RAR they were insensitive to RA, explaining why retinoic acid works in some APL patients but not others.

Armed with this new knowledge, the MSKCC researchers set out to find ways to undo this chain of events. They knew that genetic material in a chromosome is tightly held together by proteins called histones. However, histones prevent individual gene expression. Previous studies of histones have shown that transcription repressors may work by favoring the place
'"/>

Contact: Kelli Stauning
stauningk@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
26-Jan-1998


Page: 1 2 3 4

Related biology news :

1. Veterinary Memorial Fund transforms grief into promise
2. Andres Vazquez-Torres honored with 2004 Merck Irving S. Sigal Memorial Award
3. American Society for Microbiology honors Timothy Yahr with 2004 Merck Irving S. Sigal Memorial Award
4. Childrens Memorial, TGen announce partnership
5. Webcast of NSF Director Rita Colwells Chafee Memorial Lecture
6. Director of Emory Vaccine Center to give Wistar Institutes 1999 Tadeusz J. Wiktor Memorial lecture
7. Snapshot of new drug marks a major advance by Memorial Sloan-Kettering researchers
8. Chern Memorial Award Presented To Wistar Institute Postdoctoral Fellow
9. APS announces four 2004 Young Investigators awards
10. EMBO Young Investigators 2000 2002
11. Investigators use guilt-by-association strategy to track potential cancer causing genes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2017)... ROCKVILLE CENTRE, N.Y. , March 27, 2017 ... by Healthcare Information and Management Systems Society (HIMSS) ... Analytics Outpatient EMR Adoption Model sm . In ... top 12% of U.S. hospitals using an electronic ... recognized CHS for its high level of EMR ...
(Date:3/24/2017)... , March 24, 2017 The Controller General ... Controller Mr. Abdulla Algeen have received the prestigious international IAIR ... Continue Reading ... ... picture) and Deputy Controller Abdulla Algeen (small picture on the right) have ...
(Date:3/24/2017)... 2017 Research and Markets has announced the ... & Trends - Industry Forecast to 2025" report to their ... The Global ... CAGR of around 15.1% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
Breaking Biology News(10 mins):
(Date:3/27/2017)... Roka Bioscience, Inc. (NASDAQ: ROKA), a molecular diagnostics company focused ... pathogens,  today announced that Mary Duseau , CEO will ... March 29 at 9:50am ET. The conference will be held ... Roka Bioscience ... Roka Bioscience is a molecular diagnostics company focused ...
(Date:3/27/2017)... ... March 27, 2017 , ... IsoPlexis ... against cancer, autoimmune disease and more through a single-cell precision engineering platform, today ... analysis platform developed in the laboratory of Dr. James Heath at the ...
(Date:3/27/2017)... 27, 2017 Cousins Properties (NYSE: CUZ ... biotechnology companies, has signed a 10-year, approximately 125,000 square-foot lease ... asset located in the Westshore submarket of Tampa, ... Amgen has chosen Corporate Center for their new location in ... president and chief executive officer of Cousins Properties. "Amgen is ...
(Date:3/27/2017)... ... March 27, 2017 , ... Biopsies from non-small ... samples with limited tumor content in a large background of normal or wild ... the need for reliable detection of low abundance somatic mutations, particularly in small ...
Breaking Biology Technology:
Cached News: